United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
UTHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for UNITED THERAPEUTICS Corp. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 57th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 29.17%. In terms of the factors that were most noteworthy in this DCF analysis for UTHR, they are:
UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 34.82% of tickers in our DCF set.
UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 21.66. This coverage rate is greater than that of 87.38% of stocks we're observing for the purpose of forecasting via discounted cash flows.
As a business, UNITED THERAPEUTICS Corp experienced a tax rate of about 17% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 73.87% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of UNITED THERAPEUTICS Corp? See JAZZ, CHE, HBIO, PRAH, and PBH.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.
United Therapeutics Corporation has announced that it has agreed to buy a Priority Review Voucher (PRV) for $105 million, which it plans to use with an application to get a new drug approved by the U.S. Food and Drug Administration (FDA). The PRV allows United Therapeutics to receive an expedited eight-month review of the new drug application, instead of the standard twelve-month review period. United Therapeutics (UTHR) intends to apply the PRV to get approval for Tyvaso DPI, a pulmonary arterial hypertension (PAH) treatment that improves exercise ability in patients.
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million.The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration (“FDA”) of DANYELZA®, for the treatment of refractory/relapsed high-risk neuroblastoma.Under the terms of the Company’s license agreement with Memorial Sloan Kettering Cancer Center (“MSK”), Y-mAbs is entitled to reta...
United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for priority review and provides for an expedited eight-month review, instead of the standard twelve-month review period. Following the close of the transaction, United Therapeutics intends to apply the PRV to its NDA for Tyvaso DPI, expected in the first half of 2021.